Frank Rimerman Advisors LLC lessened its position in Danaher Co. (NYSE:DHR – Free Report) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,907 shares of the conglomerate’s stock after selling 141 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Danaher were worth $3,881,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Kentucky Retirement Systems Insurance Trust Fund raised its holdings in Danaher by 11.6% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock worth $4,874,000 after acquiring an additional 2,202 shares during the period. ORG Partners LLC increased its holdings in shares of Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares during the period. Generate Investment Management Ltd bought a new position in shares of Danaher during the 4th quarter worth about $8,044,000. Stifel Financial Corp increased its holdings in shares of Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after purchasing an additional 11,216 shares during the period. Finally, Compass Capital Management Inc. increased its holdings in shares of Danaher by 4.8% during the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after purchasing an additional 10,994 shares during the period. Institutional investors own 79.05% of the company’s stock.
Insider Transactions at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 11.10% of the stock is owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Analysis on DHR
Danaher Price Performance
Shares of DHR stock opened at $211.09 on Friday. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The firm’s 50 day moving average is $220.07 and its 200-day moving average is $240.82. The firm has a market capitalization of $150.87 billion, a price-to-earnings ratio of 39.98, a PEG ratio of 2.66 and a beta of 0.82. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the business earned $2.09 EPS. Sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.
Danaher Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio is presently 24.24%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- How to Use the MarketBeat Excel Dividend Calculator
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Investing in Commodities: What Are They? How to Invest in Them
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to Calculate Inflation Rate
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.